AbbVie combines advanced science, expertise and passion to solve serious health issues and have a remarkable impact on people’s lives. Read through our press releases to see our latest efforts to improve patient care.

If you are a member of the news media and have questions or need additional information, please contact our Communications Team.

   Clear Filter

Mar 09, 2020

AbbVie Announces Extension of Expiration Date for Exchange Offers for Allergan Notes

NORTH CHICAGO, Ill., March 9, 2020 /PRNewswire/ -- AbbVie Inc. (NYSE:ABBV) ("AbbVie") announced today the extension of the expiration date of the offers to exchange (each, an "Exchange Offer" and, collectively, the "Exchange Offers") any and all outstanding notes of certain series issued by Allergan Finance, LLC ("Allergan Finance"), Allergan, Inc. ("Allergan Inc"), Allergan Sales, LLC ("Allergan Sales") and Allergan Funding SCS ("Allergan Funding" and, together with Allergan Finance, Allergan Inc and Allergan Sales, "Allergan") (the "Allergan Notes") for new notes to be issued by AbbVie (the "AbbVie Notes") and the related consent solicitations (each, a "Consent Solicitation" and, collectively, the "Consent Solicitations") being made by AbbVie on behalf of Allergan to adopt certain amendments to each of the indentures (each, an "Allergan Indenture") governing the Allergan Notes. AbbVie hereby extends such expiration date from 5:00 p.m., New York City time, on March 13, 2020 to 5:00 p.m., New York City time, on March 27, 2020 (as the same may be further extended, the "Expiration Date").

Mar 09, 2020

AbbVie Partnering with Global Authorities to Determine Efficacy of HIV Drug in Treating COVID-19

NORTH CHICAGO, Ill., March 9, 2020 /PRNewswire/ -- AbbVie (NYSE:ABBV) today confirmed the company's activities in the fight to address the COVID-19 public health crisis, including supporting the experimental use of the HIV medicine, Kaletra/Aluvia (lopinavir/ritonavir) to determine its efficacy in the treatment of COVID-19.

Mar 06, 2020

European Commission Grants AbbVie Marketing Authorization Shortening MAVIRET® (glecaprevir/pibrentasvir) Treatment Duration to Eight Weeks for Treatment-Naïve Chronic HCV Patients with Genotype 3 and Compensated Cirrhosis

NORTH CHICAGO, Ill., March 6, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the European Commission has approved a change to the marketing authorization for MAVIRET® (glecaprevir/pibrentasvir) to shorten once-daily treatment duration from 12 to 8 weeks in treatment-naïve, compensated cirrhotic, chronic hepatitis C (HCV) patients with genotype (GT) 3 infection. MAVIRET was already indicated as an 8-week, pan-genotypic (GT1-6), once-daily regimen for treatment-naïve HCV patients without cirrhosis, and as an 8-week, once-daily regimen for treatment-naïve GT 1, 2, 4, 5 and 6 HCV patients with compensated cirrhosis.1*

Mar 03, 2020

AbbVie and Allergan Receive Final European Approval to Close Pending Transaction

NORTH CHICAGO, Ill. and DUBLIN, March 3, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, and Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that the European Commission has approved the divestiture of brazikumab, an investigational IL-23 inhibitor in development for autoimmune diseases, to AstraZeneca. The European Commission's approval of AbbVie's pending acquisition of Allergan in January was conditional upon the divestiture of brazikumab to a suitable purchaser. The transaction remains subject to additional customary closing conditions, but the European Commission's final approval clears the pathway in Europe to close the pending transaction.

Feb 28, 2020

AbbVie Provides Update from Phase 3 Study Evaluating VENCLEXTA® (venetoclax) in Combination with Low-Dose Cytarabine in Newly-Diagnosed Patients with Acute Myeloid Leukemia (AML)

NORTH CHICAGO, Ill., Feb. 28, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the VIALE-C (M16-043) trial of venetoclax (VENCLEXTA®) in combination with low-dose cytarabine (LDAC) versus LDAC in combination with placebo did not meet its primary endpoint of statistically significant improvement of overall survival (OS) for patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy at the time of the planned analysis.3

Feb 24, 2020

AbbVie Announces Extension of Expiration Date for Exchange Offers for Allergan Notes

NORTH CHICAGO, Ill., Feb. 24, 2020 /PRNewswire/ -- AbbVie Inc. (NYSE:ABBV) ("AbbVie") announced today the extension of the expiration date of the offers to exchange (each, an "Exchange Offer" and, collectively, the "Exchange Offers") any and all outstanding notes of certain series issued by Allergan Finance, LLC ("Allergan Finance"), Allergan, Inc. ("Allergan Inc"), Allergan Sales, LLC ("Allergan Sales") and Allergan Funding SCS ("Allergan Funding" and, together with Allergan Finance, Allergan Inc and Allergan Sales, "Allergan") (the "Allergan Notes") for new notes to be issued by AbbVie (the "AbbVie Notes") and the related consent solicitations (each, a "Consent Solicitation" and, collectively, the "Consent Solicitations") being made by AbbVie on behalf of Allergan to adopt certain amendments to each of the indentures (each, an "Allergan Indenture") governing the Allergan Notes. AbbVie hereby extends such expiration date from 5:00 p.m., New York City time, on February 28, 2020 to 5:00 p.m., New York City time, on March 13, 2020 (as the same may be further extended, the "Expiration Date").

Feb 20, 2020

AbbVie Declares Quarterly Dividend

NORTH CHICAGO, Ill., Feb. 20, 2020 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.18 per share. 

Feb 19, 2020

AbbVie to Present at the Cowen 40th Annual Health Care Conference

NORTH CHICAGO, Ill., Feb. 19, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Cowen 40th Annual Health Care Conference on Wednesday, March 4, 2020.  Michael Severino, M.D., vice chairman and president and Robert A. Michael, executive vice president and chief financial officer, will present at 10:20 a.m. Central time.   

Feb 11, 2020

AbbVie to Present at the SVB Leerink 9th Annual Global Healthcare Conference

NORTH CHICAGO, Ill., Feb. 11, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the SVB Leerink 9th Annual Global Healthcare Conference on Tuesday, February 25.  Michael Severino, M.D., vice chairman and president and Robert A. Michael, executive vice president and chief financial officer, will present at 9:30 a.m. Central time.   

Feb 07, 2020

AbbVie Reports Full-Year and Fourth-Quarter 2019 Financial Results

NORTH CHICAGO, Ill., Feb. 7, 2020 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial results for the fourth quarter and full year ended December 31, 2019.